Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of dasiglucagon for rescue treatment of hypoglycemia in type 1 diabetes
2017-002449-31Phase 3Completed
- Sponsor
- Zealand Pharma
- Start
- Oct 2017
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dasiglucagon in diabetes mellitus type 1 (T1D) and hypoglycaemia (3 arms), sponsored by Zealand Pharma. Primary endpoint: Time to plasma glucose recovery. Started Oct 2017; status: completed.
02
Drugs
dasiglucagon
03
Conditions
diabetes mellitus type 1 (T1D)hypoglycaemia
Beyond the preview
Go deeper on 2017-002449-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002449-31.